Repotrectinib 40mg Cap
Product Overview
| Generic Name | Repotrectinib 40mg Cap |
| Brand Name(s) | Augtyro™ |
| Category | Antineoplastic / Cancer |
| Form | Hard shell capsules; oral use |
| Strength | 40 mg; 160 mg |
| Therapeutic Class | Antineoplastic agent; kinase inhibitor |
| ATC Code | L01EX28 |
Manufacturing & Regulatory
| Manufacturer | Bristol-Myers Squibb |
| GMP Compliance | WHO-GMP, EU-GMP |
| COFEPRIS | CNIS / Clave: No identificada en Compendio/CNIS público |
Logistics & Export
| MOQ | 10 Units |
| Shelf Life | 12-18 Months |
| Storage | store below 25°C |
| Incoterms | EXW |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | batch-specific CoA / Certificate of Conformance / batch release documentation from BMS |
| SDS-Safety Data Sheet (PDF) | Upon Request, not publicly posted |
| CTD Summary (PDF) | Not publicly available as parallel traded molecule |
Special Notes
An oral kinase inhibitor indicated for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer